Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis
Autore:
Haguenauer, D; Welch, V; Shea, B; Tugwell, P; Adachi, JD; Wells, G;
Indirizzi:
Univ Ottawa, Ottawa Hosp, Clin Epidemiol Unit, Ottawa, ON K1N 5R2, Canada Univ Ottawa Ottawa ON Canada K1N 5R2 iol Unit, Ottawa, ON K1N 5R2, Canada Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON, Canada Univ Ottawa OttawaON Canada , Ottawa Hosp, Dept Med, Ottawa, ON, Canada McMaster Univ, St Josephs Hosp, Dept Med, Hamilton, ON, Canada McMaster Univ Hamilton ON Canada hs Hosp, Dept Med, Hamilton, ON, Canada
Titolo Testata:
OSTEOPOROSIS INTERNATIONAL
fascicolo: 9, volume: 11, anno: 2000,
pagine: 727 - 738
SICI:
0937-941X(2000)11:9<727:FFTTOP>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
RELEASE SODIUM-FLUORIDE; BONE-DENSITY; CALCIUM CITRATE; CLINICAL-TRIALS; VITAMIN-D; VERTEBRAL FRACTURES; END-POINTS; THERAPY; MONOFLUOROPHOSPHATE; WOMEN;
Keywords:
bone mineral density; fluoride; fracture; meta-analysis; osteoporosis; randomized controlled trials;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
72
Recensione:
Indirizzi per estratti:
Indirizzo: Haguenauer, D Univ Ottawa, Ottawa Hosp, Clin Epidemiol Unit, C406,Civ Site,1053 Carling Ave, Ottawa, ON K1N 5R2, Canada Univ Ottawa C406,Civ Site,1053 Carling Ave Ottawa ON Canada K1N 5R2
Citazione:
D. Haguenauer et al., "Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis", OSTEOPOR IN, 11(9), 2000, pp. 727-738

Abstract

We conducted an efectiveness meta-analysis to determine the efficacy of fluoride therapy on bone loss, vertebral and nonvertebral fractures and side effects in postmenopausal women. A literature search was conducted on MEDLINE, Current Contents and the Cochrane Controlled Trial Registry. Two independent reviewers selected randomized controlled trials which met predetermined inclusion criteria. They independently extracted data using predetermined forms and assessed the methodologic quality of the trials using a validated scale. For dichotomous outcomes, the relative risk (RR) was calculated, and for continuous outcomes, the weighted mean difference (WMD) of percentage change from baseline was calculated. Where heterogeneity existed (determined by a chi-square test) a random effects model was used. Eleven studies (1429 subjects) met the inclusion criteria. The increase in lumbar spine bone mineral density (BMD) was found to be higher in the treatment group thanin the control group with a WMD 8.1% (95% CI: 7.15, 9.09) after 2 years oftreatment and 16.1% (95% CI: 14.65, 17.5) after 4 years. The RR for new vertebral fractures was not significant at 2 years [0.87 (95% CI: 0.51, 1.46)] or at 4 years [0.9 (95% CI: 0.71, 1.14)]. The RR for new nonvertebral fractures was not significant at 2 years [1.2 (95% CI: 0.68, 2.10)] but was increased at 4 years in the treated group [1.85 (95% CT: 1.36, 2.50)], especially if used at high doses and in a non-slow-release form. The RR for gastrointestinal side effects was not significant at 2 years [2.18 (95% CI: 0.86, 1.21)] but was increased at 4 years in the treated group [2.18 (95% CI: 1.69, 4.57)], especially if fluoride was used at high doses and in a non-slow-release form. The number of withdrawals and dropouts was not different between treated and control groups at 2 and 4 years. Thus, although fluoride has an ability to increase bone mineral density at the lumbar spine, it does not result in a reduction in vertebral fractures. Increasing the dose of fluoride increases the risk of nonvertebral fractures and gastrointestinal side effects without any effect on the vertebral fracture rate.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/05/20 alle ore 15:23:50